Paratek Pharmaceuticals Set To Explode As The Holy Grail Of Antibiotics Omadacycline Nears FDA Approval


Omadacycline has broad spectrum activity and is effective in both an IV and oral form making it ideal for resistant infections. First new class of antibiotics in 30 years.

Has completed three successful Phase 3 clinical trials in CABP and ABSSSI and reached the highest confidence intervals ever achieved for an antibiotic. Approval expected in 2018.

Several large pharma companies reported to be interested in acquiring the company.

I have been in the healthcare field for quite some time and luckily been pretty successful in determining when a small cap biotech has a product that is likely to progress in clinical trials or partner with a large pharma company. Both of these situations can lead to big pops in stock price. Those that follow my articles can see these examples in Medivation (NASDAQ:MDVN), MEI Pharma (NASDAQ:MEIP), Ignyta (NASDAQ:RXDX), Geron (NASDAQ:GERN), Cytokinetics (NASDAQ:CYTK), etc. Finding undervalued biotech stocks in today’s market is not easy, but Paratek Pharmaceuticals (NASDAQ:PRTK) checks a lot of the boxes I look at when finding an undervalued stock with a lot of upside. Paratek is focused on the neglected antibiotics space and has a big winner in its broad spectrum Omadacycline antibiotic that is nearing FDA approval in several different types of infections. Its ability to develop an antibiotic that is effective in treating a wide range of bacteria and infections, has no known cross-resistance, once daily dosing with no adjustments needed, no drug interaction issues, and on top of all this, has both an IV and oral option is remarkable. With these attributes, it is not surprising that Omadacycline is being billed as the next big blockbuster antibiotic, and with that, pharma companies have started to show interest in this space again.

In my opinion, Paratek is a steal at current valuation of ~$500M with over $160M of cash on hand, Omadacycline, which is as close to a guarantee for FDA approval as you can get with 3 overwhelmingly successful clinical trials in the books, and substantial buyout rumors swirling. With several catalysts on the horizon in the short term, I think Paratek could easily double from current levels.

☑Read more

عضویت در کانال زیست فن☑

Paratek Pharmaceuticals Set To Explode As The Holy Grail Of Antibiotics Omadacycline Nears FDA Approval

Rate this post
نمایش بیشتر

نوشته‌های مشابه

دیدگاهتان را بنویسید

نشانی ایمیل شما منتشر نخواهد شد. بخش‌های موردنیاز علامت‌گذاری شده‌اند *

همچنین ببینید

دکمه بازگشت به بالا